ATOMIC (Academic Thoracic Oncology Medical Investigators Consortium), met at the IASLC 2023 Targeted Therapies of Lung Cancer symposium in February in Santa Monica.
Continue readingContact Us: 1-518-583-0095 
We’re Hiring… Join Our Team!
International Thoracic Oncology Experts – ESMO Panel Discussion
ATOMIC Director Ross Camidge MD, PhD, draws out novel opinions across the field of thoracic oncology from a panel of international experts discussing their favorite ESMO abstracts from 2022.
Continue readingIndustry News: Brain MRI surveillance needed for TKl-treated ALK or ROS7-positive NSCLC
Retrospective data showed how common central nervous system metastases are among patients with non-small cell lung cancer and ALK or ROS1 alterations who have been treated with tyrosine kinase inhibitors.
Continue readingPharmaVoice Interview with Dr. D. Ross Camidge, Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC)
Watch the PharmaVoice One on One video interview below to learn more about the latest in Thoracic Oncology research from Dr. D. Ross Camidge, Director of the Academic Thoracic Oncology Medical Investigators Consortium and Director of Thoracic Oncology at the University of Colorado.
Continue readingCRITERIUM, Inc. CRO’s ATOMIC PI Leora Horn, MD, Highlighted in ASCOPOST Article
ATOMIC Investigator, Leora Horn, MD, Director of Clinical Research at Vanderbilt University’s Ingram Cancer Center, was highlighted in a recent biographical article by the ASCOPOST about her “Journey to a Career in Oncology…” that has taken her from Johannesburg, South Africa to Toronto, Canada to Kentucky.
Continue readingCRITERIUM, Inc. CRO’s ATOMIC PI’s Co-Author on Medicine Matters
Two ATOMIC Investigators, Natasha B. Leighl, MD, MMSc, FRCPC, and Stephen V. Liu, MD, co-authored an article published online in Medicine Matters outlining how “immunotherapy has forever changed the management of non-small cell lung cancer (NSCLC).”
Continue readingCRITERIUM, Inc. CRO’s Two Consortia Directors Receive Promotions, Tenure at UCD
Criterium, Inc., a full-service CRO is pleased to announce the promotions of our two newest consortia directors, Drs D. Ross Camidge and Peter Kabos, both from the University of Colorado. Dr Camidge, Director for the ATOMIC Consortia for Thoracic and Lung Cancers, was recently promoted from his current position of Associate Professor, Division of Medical Oncology to “Professor with Tenure”. Dr Kabos, Director for the ABRCC Consortia for Breast Cancer, was recently promoted from his current position of Assistant Professor, Division of Medical Oncology to “Associate Professor”.
Continue readingCRITERIUM, Inc. Announces the Formation of Two New Oncology Consortia
Criterium, Inc., a full service global CRO is pleased to announce the formation of its two new oncology consortia: ATOMIC (The Academic Thoracic Oncology Medical Investigator’s Consortium) focusing on Thoracic and Lung Cancers, and ABRCC (The Academic Breast Cancer Consortium), dedicated to Breast Cancer research.
Continue readingCRITERIUM, Inc. CRO’s ATOMIC Presenters Take the Stage at the IASLC 19th WCLC Conference
At the 19th IASLC World Conference on Lung Cancer in Toronto, Canada, the top 5 abstracts were presented in the Presidential Plenary Session on Tuesday Sept 25th. Out of the 5 presentations, two were presented by ATOMIC members (Stephen Liu, MD, on Impower 133 and Dr. Ross Camidge, MD, PhD, on ALTA-1L) each of which were supported with an associated synchronous New England of Journal of Medicine publication
Continue reading